Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Biotechnology

Healthcare
$127.16 +1.54%

+$1.72 today

Market cap
$8.30B
Beta
1.83
P/E (TTM)
-64.2
EPS (TTM)
-$1.76
52W Low $49.38High $114.00

Volume 0.43M

Average 0.72M

PTGX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Protagonist Therapeutics, Inc.NASDAQ: PTGX

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q2 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 99.9%, down 0.1 pp year over year. Over 3 fiscal years it narrowed by 2.7 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+0.7 pp QoQ
Last fiscal yearDec 2025
97.3%-2.7 pp YoY
LTMJun 2026
99.9%-0.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year-2.7 pp——
3 years-2.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
97.3%
Year-over-year change
-2.7pp

Gross Margin vs competitors

How PTGX compares with its peers on the latest reported figures

  • PTGX's LTM Jun 2026 gross margin of 99.9% is the 3rd highest of the 5 companies compared; the peer median is 88.2%.
  • Its year-over-year change of -0.1 pp is the lowest of 3, against a peer median of +111.2 pp.
  • Over three fiscal years its change of -2.7 pp compares with a peer median of +437.8 pp.
PTGX Competitors Peer median
Gross Margin for PTGX and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 2026116.4% +166.6 pp+862.2 pp
IMVTImmunovant, Inc.LTM Sep 2026100.0% ——
PTGXProtagonist Therapeutics, Inc.LTM Jun 202699.9% -0.1 pp-2.7 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
SYRESpyre Therapeutics, Inc.LTM Sep 202650.0% ——
IRONDisc Medicine, Inc.FY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
IMUXImmunic, Inc.FY2025— ——
Peer median (excluding PTGX) 88.2%+111.2 pp+437.8 pp

Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.36M26.58M60M434.43M46.02M
Cost of Revenue00001.23M
Gross Profit27.36M26.58M60M434.43M44.79M
Gross Margin100.0%100.0%100.0%100.0%97.3%
Research & Development126.01M126.22M120.16M138.13M159.29M
Selling, General & Admin27.2M31.74M33.49M43.46M44.85M
Operating Expenses153.2M157.95M153.65M181.59M202.92M
Depreciation & Amortization2.78M3.37M3.31M2.96M1.28M
EBITDA(122.78M)(124.02M)(75.64M)282.37M(128.03M)
EBITDA Margin-448.8%-466.6%-126.1%65.0%-278.2%
Operating Income(125.85M)(131.37M)(93.65M)252.84M(158.13M)
Operating Margin-460.0%-494.2%-156.1%58.2%-343.6%
Interest Income443K4.06M14.9M26.32M28.79M
Interest Expense00000
Other Income / Expenses294K3.98M14.7M26.57M28.82M
Income Before Tax(125.55M)(127.39M)(78.96M)279.41M(129.31M)
Pre-Tax Margin-458.9%-479.3%-131.6%64.3%-281.0%
Income Tax Expense0004.22M838K
Net Income(125.55M)(127.39M)(78.96M)275.19M(130.15M)
Net Margin-458.9%-479.3%-131.6%63.3%-282.8%
EPS (Basic)(2.65)(2.52)(1.39)4.47(2.05)
EPS (Diluted)(2.65)(2.52)(1.39)4.23(2.05)
Weighted Avg Shares46.32M49.04M56.76M61.57M63.57M
Weighted Avg Shares (Diluted)46.32M49.04M56.76M65.08M63.57M

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Intrinsic Alpha fair value

Locked

Current Price

$127.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.